[Novel medical treatment modalities in hematology].
Today several monoclonal antibodies, including the anti-CD20 antibody (rituximab), the anti-CD52 antibody (alemtuzumab) and the anti-CD33 antibody (gemtuzumab ozogamacin) are all integrated in the therapeutic armamentarium of patients with malignant lymphoma, chronic lymphocytic leukaemia and acute myelogenous leukaemia, respectively. Rituximab has also been shown to be highly effective in the treatment of refractory autoimmune haemolytic anemias, idiopathic thrombocytopenia, and relapsing thrombotic thrombocytopenic purpura. New signal transduction inhibitors, dasatinib and nilotinib, are being used in patients with chronic myelogeneous leukaemia who develop resistance to imatinib. Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases.
Herlev Hospital, Haematologisk Afdeling L, Herlev. hans.hasselbalch@dadlnet.dk
Hans Carl
HC
Hasselbalch
Henrik
H
Birgens
Inge Høgh
IH
Dufva
Anne-Marie
AM
Dalseg
Peter de Nully
Pde N
Brown
Morten Krogh
MK
Jensen
Anette
A
Vangsted
D000617:Aminoglycosides / Q000627:therapeutic use; D000743:Anemia, Hemolytic / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001565:Benzoates / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002227:Carbazoles / Q000627:therapeutic use; D002352:Carrier Proteins / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D000069439:Dasatinib; D005663:Furans; D000079982:Gemtuzumab; D006402:Hematologic Diseases / Q000188:drug therapy*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007155:Immunologic Factors / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D000077269:Lenalidomide; D007938:Leukemia / Q000188:drug therapy*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D009101:Multiple Myeloma / Q000188:drug therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy; D011719:Pyrazines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011961:Receptors, Fc / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D000069283:Rituximab; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D013926:Thrombopoietin; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003521:Cyclopropanes
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001549:Benzamides; D001565:Benzoates; D001897:Boronic Acids; D000069286:Bortezomib; D002227:Carbazoles; D002352:Carrier Proteins; D003520:Cyclophosphamide; D000069439:Dasatinib; D005663:Furans; D000079982:Gemtuzumab; D006834:Hydrazines; D000068877:Imatinib Mesylate; D007155:Immunologic Factors; D007211:Indoles; D000077269:Lenalidomide; D010879:Piperazines; D011719:Pyrazines; D011720:Pyrazoles; D011743:Pyrimidines; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D000069283:Rituximab; D013792:Thalidomide; D013844:Thiazoles; D013926:Thrombopoietin; D014740:Vidarabine; C484810:tozasertib; D003521:Cyclopropanes; C481642:eculizumab; C119379:lestaurtinib; C498826:nilotinib; C488777:romiplostim; C024352:fludarabine; C520809:eltrombopag